TuisMEHCQ • OTCMKTS
add
23andMe Holding Co
Vorige sluiting
$4,24
Dagwisseling
$4,05 - $4,39
Jaarwisseling
$0,47 - $10,81
Markkapitalisasie
117,60 m USD
Gemiddelde volume
575,71 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
OTCMKTS
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Mrt. 2025info | J/J-verandering |
---|---|---|
Inkomste | 45,15 m | -29,49% |
Bedryfskoste | 65,51 m | -34,62% |
Netto inkomste | -99,35 m | 52,43% |
Netto winsgrens | -220,04 | 32,54% |
Wins per aandeel | — | — |
EBITDA | -45,06 m | 35,08% |
Effektiewe belastingkoers | 0,00% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Mrt. 2025info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 38,25 m | -82,33% |
Totale bates | 159,89 m | -59,54% |
Totale aanspreeklikheid | 186,64 m | -9,68% |
Totale ekwiteit | -26,74 m | — |
Uitstaande aandele | 27,54 m | — |
Prys om te bespreek | -4,37 | — |
Opbrengs op bates | -54,88% | — |
Opbrengs op kapitaal | -230,70% | — |
Kontantvloei
Netto kontantverandering
(USD) | Mrt. 2025info | J/J-verandering |
---|---|---|
Netto inkomste | -99,35 m | 52,43% |
Kontant van bedrywe | -40,73 m | -57,97% |
Kontant van beleggings | -734,00 k | 65,80% |
Kontant van finansiering | -529,00 k | -126,45% |
Netto kontantverandering | -41,99 m | -61,95% |
Beskikbare kontantvloei | -82,91 m | -285,64% |
Meer oor
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Gestig
Apr. 2006
Webwerf
Werknemers
261